Biogen Inc BIIB
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Biogen Inc is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $32.5B, based in the USA.
It employs about 7,500 people and has been listed since Sep 16, 1991.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 39.6 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 3% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 13.9 — they expect higher earnings.
The average analyst price target is 238.18, 8% above the current price (their view, not ours).
The stock sits at 89% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 4 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (22 vs 1).
What changed this week
Over the past week the stock fell 3.4% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
It set a new one-year high this week.
This week's news
- Biogen phase 2 litifilimab data boosts lupus candidate seekingalpha.com · 2026-10-02
- Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program seekingalpha.com · 2026-10-02
- Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus finance.yahoo.com · 2026-10-02
- Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? finance.yahoo.com · 2026-10-02
- Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks finance.yahoo.com · 2026-10-01
- 1 Profitable Stock Worth Investigating and 2 We Ignore finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.